Evaluating "superiority", "equivalence" and "non-inferiority" in clinical trials
Clinical studies are usually performed with the aim of justifying that a new treatment approach is "superr rior" to the common standard approach (active control) with respect to benefits. In a general sense, this justification is carried out on the basis of the "null hypothesis signif...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
King Faisal Specialist Hospital and Research Centre
2007-01-01
|
| Series: | Annals of Saudi Medicine |
| Online Access: | http://www.saudiannals.net/article.asp?issn=0256-4947;year=2007;volume=27;issue=4;spage=284;epage=288;aulast=Turan |
| _version_ | 1818853526779985920 |
|---|---|
| author | Turan Fatma Senocak Mustafa |
| author_facet | Turan Fatma Senocak Mustafa |
| author_sort | Turan Fatma |
| collection | DOAJ |
| description | Clinical studies are usually performed with the aim of justifying that a new treatment approach is "superr rior" to the common standard approach (active control) with respect to benefits. In a general sense, this justification is carried out on the basis of the "null hypothesis significance test" with the P value based on this test used for justification. Today, new drugs differ so little from existing ones that factors such as cost and side effects affect the choice of therapy, when the bioavailability of treatment methods are found equivalent. Therefore, the aim of comparative clinical trials has extended beyond showing that a treatment is "superior" and now attempts to show that new treatments are "equal" and "nonrinferior" to existing treatments. New approaches have become necessary since the classical null hypothesis approach is insufrr ficient to justify the use of new agents, especially in cases of "equivalence" and "nonrinferiority". This new approach to justification makes use of the "clinical equivalence interval", , which determines the limits of the differences between specific endpoints that can be regarded as clinically "equal" to the value that was prerspecified based on studies of established therapies. It also makes use of the quantitativerbased "conrr fidence intervals" as the criteria for statistical justification. Many analyses can be done confidently when these tools are applied and the data are interpreted correctly. |
| first_indexed | 2024-12-19T07:38:13Z |
| format | Article |
| id | doaj.art-563af266ad34477bb15f640ac9f5a085 |
| institution | Directory Open Access Journal |
| issn | 0256-4947 0975-4466 |
| language | English |
| last_indexed | 2024-12-19T07:38:13Z |
| publishDate | 2007-01-01 |
| publisher | King Faisal Specialist Hospital and Research Centre |
| record_format | Article |
| series | Annals of Saudi Medicine |
| spelling | doaj.art-563af266ad34477bb15f640ac9f5a0852022-12-21T20:30:32ZengKing Faisal Specialist Hospital and Research CentreAnnals of Saudi Medicine0256-49470975-44662007-01-01274284288Evaluating "superiority", "equivalence" and "non-inferiority" in clinical trialsTuran FatmaSenocak MustafaClinical studies are usually performed with the aim of justifying that a new treatment approach is "superr rior" to the common standard approach (active control) with respect to benefits. In a general sense, this justification is carried out on the basis of the "null hypothesis significance test" with the P value based on this test used for justification. Today, new drugs differ so little from existing ones that factors such as cost and side effects affect the choice of therapy, when the bioavailability of treatment methods are found equivalent. Therefore, the aim of comparative clinical trials has extended beyond showing that a treatment is "superior" and now attempts to show that new treatments are "equal" and "nonrinferior" to existing treatments. New approaches have become necessary since the classical null hypothesis approach is insufrr ficient to justify the use of new agents, especially in cases of "equivalence" and "nonrinferiority". This new approach to justification makes use of the "clinical equivalence interval", , which determines the limits of the differences between specific endpoints that can be regarded as clinically "equal" to the value that was prerspecified based on studies of established therapies. It also makes use of the quantitativerbased "conrr fidence intervals" as the criteria for statistical justification. Many analyses can be done confidently when these tools are applied and the data are interpreted correctly.http://www.saudiannals.net/article.asp?issn=0256-4947;year=2007;volume=27;issue=4;spage=284;epage=288;aulast=Turan |
| spellingShingle | Turan Fatma Senocak Mustafa Evaluating "superiority", "equivalence" and "non-inferiority" in clinical trials Annals of Saudi Medicine |
| title | Evaluating "superiority", "equivalence" and "non-inferiority" in clinical trials |
| title_full | Evaluating "superiority", "equivalence" and "non-inferiority" in clinical trials |
| title_fullStr | Evaluating "superiority", "equivalence" and "non-inferiority" in clinical trials |
| title_full_unstemmed | Evaluating "superiority", "equivalence" and "non-inferiority" in clinical trials |
| title_short | Evaluating "superiority", "equivalence" and "non-inferiority" in clinical trials |
| title_sort | evaluating superiority equivalence and non inferiority in clinical trials |
| url | http://www.saudiannals.net/article.asp?issn=0256-4947;year=2007;volume=27;issue=4;spage=284;epage=288;aulast=Turan |
| work_keys_str_mv | AT turanfatma evaluatingsuperiorityequivalenceandnoninferiorityinclinicaltrials AT senocakmustafa evaluatingsuperiorityequivalenceandnoninferiorityinclinicaltrials |